{"log_id": 8062679026525504562, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 0.001111, "average": 0.957839, "min": 0.907068}, "location": {"width": 139, "top": 148, "height": 34, "left": 77}, "words": "肝功能受"}, {"probability": {"variance": 0.019299, "average": 0.908453, "min": 0.504071}, "location": {"width": 1046, "top": 201, "height": 50, "left": 128}, "words": "肝功能受损会使依维莫司暴露量增加(参见【注意事项】)。按如下方式进行给药训整"}, {"probability": {"variance": 0.012621, "average": 0.931051, "min": 0.507547}, "location": {"width": 1177, "top": 256, "height": 54, "left": 192}, "words": "轻度肝功能受损( child-pugh A级:推荐剂量为.5mg/日;如果不能好地受,可将剂量降至"}, {"probability": {"variance": 0.004861, "average": 0.913794, "min": 0.821523}, "location": {"width": 84, "top": 315, "height": 34, "left": 194}, "words": "5mg/日"}, {"probability": {"variance": 0.022985, "average": 0.91846, "min": 0.356081}, "location": {"width": 1177, "top": 365, "height": 54, "left": 192}, "words": "中度肝功能受损(Chd- Pugh B):推荐剂量是5mgil;如果不能很好地耐受,可将剂量降"}, {"probability": {"variance": 0.001945, "average": 0.964384, "min": 0.895409}, "location": {"width": 98, "top": 425, "height": 27, "left": 196}, "words": "25mg/日"}, {"probability": {"variance": 0.02454, "average": 0.907778, "min": 0.403249}, "location": {"width": 1174, "top": 473, "height": 57, "left": 192}, "words": "审度功能曼损( child-pugh C级):如预期的获益高于风险,可以深用2.5g/日一次,但不得"}, {"probability": {"variance": 0.014217, "average": 0.927042, "min": 0.672092}, "location": {"width": 166, "top": 532, "height": 34, "left": 192}, "words": "超过这一剂量"}, {"probability": {"variance": 0.024727, "average": 0.919725, "min": 0.392396}, "location": {"width": 960, "top": 585, "height": 48, "left": 123}, "words": "治疗过程中,如果者肝功能( child-pugh分级)状态发生变化,应.整剂量"}, {"probability": {"variance": 0.050669, "average": 0.744426, "min": 0.362513}, "location": {"width": 457, "top": 642, "height": 34, "left": 75}, "words": "CP3A4高蛋PgP)"}, {"probability": {"variance": 0.03255, "average": 0.857222, "min": 0.457944}, "location": {"width": 1243, "top": 694, "height": 50, "left": 118}, "words": "避免用CYP3A4强效拟制剂(如糜唑、伊曲废哇、克拉霉素、扎那韦、法唑酮、沙那卡、秦利"}, {"probability": {"variance": 0.02146, "average": 0.891527, "min": 0.440782}, "location": {"width": 1142, "top": 747, "height": 50, "left": 64}, "words": "棒素、利托那韦、地韦、奈非那书、优立唑》(见【注意事项】和【药物相互作用】)"}, {"probability": {"variance": 0.018461, "average": 0.916433, "min": 0.491814}, "location": {"width": 1238, "top": 802, "height": 52, "left": 123}, "words": "当与CYP3A4和或PgP中效抑制剂(如氨普书、山那中、阿瑞匹坦、红霉素、氟康唑、维拉柏米、地"}, {"probability": {"variance": 0.036428, "average": 0.861649, "min": 0.353256}, "location": {"width": 1291, "top": 857, "height": 54, "left": 64}, "words": "尔硫卓合并用药时应速,如需要合使用中效CYP3A4J或PP抑制问,可将本品剂量降至2.5mg"}, {"probability": {"variance": 0.029401, "average": 0.893792, "min": 0.468839}, "location": {"width": 1291, "top": 912, "height": 52, "left": 66}, "words": "!。预期或量后的本品剂量可以使药时曲线下通积(ATIC)词整到不用和制剂时的AUC范围内。可以根据忠"}, {"probability": {"variance": 0.018669, "average": 0.908455, "min": 0.41588}, "location": {"width": 1291, "top": 966, "height": 54, "left": 66}, "words": "受性考虑将本品剂量从2.5mg增全5mg,如果停用中效抑制剂,在本品剂量培加前应该允许有约2-3天"}, {"probability": {"variance": 0.013429, "average": 0.942398, "min": 0.460936}, "location": {"width": 1250, "top": 1019, "height": 52, "left": 61}, "words": "的洗脱期。如果停用中效抑制剂,本品剂量应该恢复到使用中效CYP3A4和PP排制泡之前的剂量水平"}, {"probability": {"variance": 0.025518, "average": 0.906405, "min": 0.481383}, "location": {"width": 1040, "top": 1076, "height": 48, "left": 114}, "words": "在治疗中应该避免食用已知会抑制细胞色素P450和PgP活性的西、汁和其它食物"}, {"probability": {"variance": 0.012835, "average": 0.895701, "min": 0.63581}, "location": {"width": 233, "top": 1133, "height": 32, "left": 66}, "words": "CYP3A4强诱导剂"}, {"probability": {"variance": 0.025073, "average": 0.901054, "min": 0.429538}, "location": {"width": 1243, "top": 1186, "height": 52, "left": 112}, "words": "避免合并使用强效CYP3A4诱导剂(如苯妥英、卡马平、利福平、科福布丁、利福喷汀和苯巴比买)。"}, {"probability": {"variance": 0.021715, "average": 0.907731, "min": 0.397599}, "location": {"width": 1268, "top": 1241, "height": 54, "left": 57}, "words": "如思老需要合并使用效CYP3A4导剂,应考虑将本品以5mg量递增,从10mg每日一次增至20mg每日"}, {"probability": {"variance": 0.018371, "average": 0.916181, "min": 0.446867}, "location": {"width": 1296, "top": 1296, "height": 52, "left": 54}, "words": "次。根据药代动力学数据:预期增量后的本品剂量可以使AIC请整到未用导判时的AUC范圃内。然而:尚"}, {"probability": {"variance": 0.034015, "average": 0.878768, "min": 0.360827}, "location": {"width": 1296, "top": 1350, "height": 50, "left": 54}, "words": "没有在使用强效CYP3A4导剂患者中诚整价药剂量的临床数据如果停强效秀导剂本剂应恢复"}, {"probability": {"variance": 0.022512, "average": 0.917658, "min": 0.368199}, "location": {"width": 944, "top": 1405, "height": 45, "left": 57}, "words": "至服用效CYP3A4导剂之的的剂量(参见【注意事项】和【药物相互作"}, {"probability": {"variance": 0.001599, "average": 0.973777, "min": 0.837649}, "location": {"width": 797, "top": 1460, "height": 45, "left": 112}, "words": "约翰草(金丝桃)可非预期地降低依维莫可暴露量,应避使用"}, {"probability": {"variance": 0.012804, "average": 0.934133, "min": 0.546735}, "location": {"width": 592, "top": 1513, "height": 45, "left": 54}, "words": "结节性硬化症相关的室管膜下巨细胞星形细胞痛"}, {"probability": {"variance": 0.037906, "average": 0.875068, "min": 0.538163}, "location": {"width": 114, "top": 1570, "height": 32, "left": 54}, "words": "推荐剂最"}, {"probability": {"variance": 0.021097, "average": 0.931629, "min": 0.367191}, "location": {"width": 1241, "top": 1625, "height": 48, "left": 107}, "words": "推荐起始剂量为4.5mg/m每日一次。应在有结节性硬化症及其相关的室管膜下巨细胞星形细胞瘤治疗经"}, {"probability": {"variance": 0.000403, "average": 0.987069, "min": 0.938084}, "location": {"width": 308, "top": 1680, "height": 34, "left": 52}, "words": "验的专科医生指导下使用"}, {"probability": {"variance": 0.016303, "average": 0.927159, "min": 0.52583}, "location": {"width": 1216, "top": 1732, "height": 52, "left": 105}, "words": "剂量按体表面积(BSA,m2)个体化,体表面积的计算采用 diois公式,其中体重(W)的单位是千克"}, {"probability": {"variance": 0.005984, "average": 0.945932, "min": 0.77245}, "location": {"width": 297, "top": 1789, "height": 36, "left": 50}, "words": "身高(H)的单位是厘米"}, {"probability": {"variance": 0.035379, "average": 0.837946, "min": 0.465972}, "location": {"width": 395, "top": 1840, "height": 43, "left": 105}, "words": "BSA=(H0<35x072)×0.07184"}, {"probability": {"variance": 0.025709, "average": 0.894875, "min": 0.415432}, "location": {"width": 1238, "top": 1899, "height": 50, "left": 102}, "words": "对于重度肝功能受损( child-iush C级)或需要同时使用中效CYP34和或PgP抑制剂的者,推荐起始"}, {"probability": {"variance": 0.016996, "average": 0.930289, "min": 0.381652}, "location": {"width": 1266, "top": 1954, "height": 50, "left": 48}, "words": "剂量为2.5mg/m2每1一次(参见【用用量】“剂调整”)。对需要同时使用强CPY3A4导剂的患者"}, {"probability": {"variance": 0.038272, "average": 0.862103, "min": 0.380387}, "location": {"width": 1296, "top": 2009, "height": 50, "left": 45}, "words": "推荐想始剂为9mg/m2每日一(参见【用法量】“剂量调整”)请将计算所得量四五入本品最"}, {"probability": {"variance": 0.000685, "average": 0.977358, "min": 0.927139}, "location": {"width": 134, "top": 2068, "height": 32, "left": 48}, "words": "接近的规格"}], "language": 3}